Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A) Meeting Abstract

  

Authors:	Scher, H. I.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R. P.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; Landers, M. A.; Dittamore, R. V.
Abstract Title:	Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A)
Meeting Title:	53rd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	35
Issue:	15 Suppl.
Meeting Dates:	2017 Jun 2-6
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2017-05-20
Start Page:	280s
Language:	English
ACCESSION:	WOS:000411931703059
DOI:	10.1200/JCO.2017.35.15_suppl.5070
PROVIDER:	wos
Notes:	Meeting Abstract: 5070 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/147263